Myron Schwartz, MD
The Henry Kaufmann Professor of Surgery
Director of Liver Surgery
Recanati/Miller Transplantation Institute
The Mount Sinai Medical Center, New York
Dr. Schwartz graduated from Jefferson Medical College AOA in 1976. After a year of rotating internship he joined the National Health Service Corps for three years as a general practitioner in rural Virginia. Dr. Schwartz came to Mount Sinai in 1981, completed residencies in general and vascular surgery, and joined the faculty in 1987. He worked with Charles Miller, MD to establish the Mount Sinai Liver Transplant Program in 1988, and since then has devoted his career to hepatobiliary surgery and transplantation. Over the years he has served as Director of Pediatric and Adult Liver Transplantation, and more recently has focused on liver cancer. Dr. Schwartz is currently the Clinical Director of the Mount Sinai Liver Cancer Program. Together with Research Director Josep Llovet MD, Dr Schwartz has led the collaborative effort that has put Mount Sinai at the forefront world-wide in liver cancer clinical care and clinical/translational research. Dr Schwartz has been funded by the NIH through a K24 Career Development Award entitled, “Systematic Integration of Patient-Oriented Research into the Clinical Pathway for Hepatocellular Carcinoma”. He has published over 300 papers in peer-reviewed journals, as well as 21 book chapters. Dr. Schwartz is an international authority on hepatic resection and transplantation for liver cancer, a subject about which he lectures frequently both in the U.S. and around the world.In the News:
Dr. Schwartz and his work was profiled in The Daily News feature The Daily Check Up. View the PDF.
American Board of Surgery
MD, Jefferson Medical College
Mercy Catholic Medical Center
Mount Sinai Hospital
Fellowship, Vascular Surgery
Mount Sinai Hospital
English, Farsi (Persian), Hebrew, Spanish
Physician of the Year Award
Transplant Recipients International Organization
Arthur Aufses, Sr., Prize in Surgery
Alpha Omega Alpha Medical Honor Society
A Prospective Randomized Clinical Trial on 90Yttrium Trans-Arterial Radio-Embolization (Therasphere®) vs. Standard Of Care (Sorafenib) for the Treatment of Advanced Hepatocellular Carcinoma (HCC) With Portal Vein Thrombosis (PVT)
The purpose of this study is to examine whether TheraSphere is better than the current standard treatment for liver cancer (sorafenib...
A randomized, double blind, placebo-controlled, multicenter phase III study of regorafenib in patients with hepatocellular carcinoma (HCC) after sorafenib
The purpose of this study is to assess if regorafenib in combination with Best Supportive Care is safe and will slow down the growth of tumor or even shrink the tumor and result in increased survival in subjects who experienced failure of previous systemic sorafenib treatment. ...
HCC BRIDGE study: Bridge to better outcomes in HCC
The purpose of this study is to determine current treatment approaches and outcomes for patients with hepatocellular carcinoma (HCC). In addition to date of birth and dates of diagnosis(es), treatments, procedures, and hospitalizations, we will collect information on how patients...
Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J, Tabak B, Peix J, Sole M, Tovar V, Alsinet C, Cornella H, Klotzle B, Fan JB, Cotsoglou C, Thung SN, Fuster J, Waxman S, Garcia-Valdecasas JC, Bruix J, Schwartz ME, Beroukhim R, Mazzaferro V, Llovet JM. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology 2013 Apr; 144(4).
Roayaie S, Obeidat K, Sposito C, Mariani L, Bhoori S, Pellegrinelli A, Labow D, Llovet JM, Schwartz M, Mazzaferro V. Resection of hepatocellular cancer ≤2 cm: results from two Western centers. Hepatology (Baltimore, Md.) 2013 Apr; 57(4).
Mínguez B, Hoshida Y, Villanueva A, Toffanin S, Cabellos L, Thung S, Mandeli J, Sia D, April C, Fan JB, Lachenmayer A, Savic R, Roayaie S, Mazzaferro V, Bruix J, Schwartz M, Friedman SL, Llovet JM. Gene-expression signature of vascular invasion in hepatocellular carcinoma. Journal of hepatology 2011 Dec; 55(6).
Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D, Alsinet C, Cornella H, Liberzon A, Kobayashi M, Kumada H, Thung SN, Bruix J, Newell P, April C, Fan JB, Roayaie S, Mazzaferro V, Schwartz ME, Llovet JM. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology 2011 May; 140(5).
Florman S, Toure B, Kim L, Gondolesi G, Roayaie S, Krieger N, Fishbein T, Emre S, Miller C, Schwartz ME. Liver transplantation for neuroendocrine tumors. J Gastrointest Surg 2004; 8: 208-212.
Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR, Reddy KR, Harnois D, Llovet JM, Normolle D, Dalhgren J, Chia D, Lok AS, Wagner PD, Srivastava S, Schwartz M. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009 Jul; 137(1).
Roayaie S, Blume IN, Thung SN, Guido M, Fiel MI, Hiotis S, Labow DM, Llovet JM, Schwartz ME. A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology 2009 Sep; 137(3).
Schwartz M, Dvorchik I, Roayaie S, Fiel MI, Finkelstein S, Marsh JW, Martignetti JA, Llovet JM. Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers. Journal of hepatology 2008 Oct; 49(4).
Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J, Reich M, Chan JA, Glickman JN, Ikeda K, Hashimoto M, Watanabe G, Daidone MG, Roayaie S, Schwartz M, Thung S, Salvesen HB, Gabriel S, Mazzaferro V, Bruix J, Friedman SL, Kumada H, Llovet JM, Golub TR. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. The New England journal of medicine 2008 Nov; 359(19).
Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, Camerini T, Roayaie S, Schwartz ME, Grazi GL, Adam R, Neuhaus P, Salizzoni M, Bruix J, Forner A, De Carlis L, Cillo U, Burroughs AK, Troisi R, Rossi M, Gerunda GE, Lerut J, Belghiti J, Boin I, Gugenheim J, Rochling F, Van Hoek B, Majno P. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. The lancet oncology 2009 Jan; 10(1).
Roayaie S, Schwartz JD, Sung M, Emre S, Miller CM, Gondolesi G, Krieger N, Schwartz ME. Recurrence of hepatocellular carcinoma after liver transplant: Patterns and prognosis. Liver Transpl 2004; 10: 534-540.
Schwartz M. Liver transplantation for hepatocellular carcinoma. Gastroenterology 2004; 127: S268-276.
Gondolesi G, Roayaie S, Munoz L, Kim-Schluger L, Schiano T, Fishbein T, Emre S, Miller CM, Schwartz ME. Adult Living Donor Liver Transplantation for Patients with Hepatocellular Carcinoma: Extending UNOS Priority Criteria. Ann Surg 2004; 239: 142-149.
Gondolesi GE, Goldman J, Wayne M, Florman S, Schwartz ME, Miller CM, Emre S. .;.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Schwartz did not report having any of the following types of financial relationships with industry during 2015 and/or 2016: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.